Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSIn veterans with diabetes and opioid use disorder, semaglutide and tirzepatide beat insulin and SGLT2 inhibitors on 12-month overdose risk but tied metformin, sulfonylureas, and DPP-4 drugs. The verdict flips with the comparator.
A Veterans Affairs cohort of 100,038 matched pairs found GLP-1 drugs tied to no more and no fewer lymphomas, leukemias, or myelomas than an older diabetes pill. Every confidence interval crossed the line of no difference.
In a 280-person Phase 2 trial, the oral GLP-1 drug HRS-7535 cut albuminuria 32 percent more than placebo in diabetic kidney disease, even though most patients were already on SGLT2 inhibitors and finerenone.
A data firm's analysis of nearly 30,000 adults 65 and older on tirzepatide found progressive muscle loss in 0.16 percent, with most frailty signals emerging only after six months.
A Cell Reports team acetylated the N-terminus of GLP-1 and semaglutide to build G protein-biased receptor agonists that recruit less beta-arrestin, and a 2.64 angstrom cryo-EM structure pins the bias to an outward swing of extracellular loop 3. Ac-semaglutide kept lowering glucose in obese mice three days after one dose.
A target trial emulation of 57,456 weight-management patients found semaglutide users had a 12 percent lower one-year risk of new diabetes than liraglutide users (HR 0.88). The gap was absent in the first six months (HR 0.99) and only emerged after (HR 0.80). With just 57 cardiovascular events, the study had no power to compare heart risk.
A quarter-million-patient database found GLP-1 drug users were no more likely, and often less likely, to have mouth problems. Reflux was the one exception worth watching.
In 235,200 matched adults, starting tirzepatide tracked with about three-quarters lower pulmonary embolism risk than lifestyle changes alone. The edge shrank to near even against semaglutide.
A US claims study emulating a randomized trial found that whichever flagship diabetes drug patients started on, adding the other modern class lowered heart events more than adding an older pill.
A drug-target Mendelian randomization study put major depression 18 percent lower and bipolar disorder 39 percent lower for genetically predicted GLP-1 receptor activation, cutting against two years of psychiatric-safety scares built on observational data.
A TriNetX analysis of 1,688 matched pairs found GLP-1 receptor agonists cut major heart events, death, and even sepsis in dialysis patients with type 2 diabetes, a group the big outcome trials left out.
A study of more than 192 million records found tirzepatide and semaglutide carried the same risk of depression, anxiety, and suicidal thoughts, and semaglutide came out lower than the earlier GLP-1 drugs.
A meta-analysis of 11 in-vitro studies found GLP-1 drugs raised cellular energy output and cut oxidative exhaust in human cells with no body attached, then graded the evidence very low.
A prespecified SUMMIT secondary analysis split 731 obesity-related HFpEF patients by sex. Women arrived sicker and men more remodeled, but tirzepatide cut worsening-HF-or-death risk about a third in both (HR 0.66 vs 0.61, interaction P 0.81). The one sex difference: in women, symptom relief tracked weight loss.
A new analysis of the FDA's adverse-event database, published July 9 in Obstetrics & Gynecology, looked at menstrual complaints filed for female patients aged 12 to 55 on GLP-1 drugs. Semaglutide flagged for five kinds of disruption (heavy bleeding, spotting between periods, clots, infrequent periods, skipped ovulation), tirzepatide for two, and liraglutide for none. Three drugs on the same receptor, three different menstrual fingerprints, from a spontaneous-report system that can flag a signal but cannot prove cause.